FDA Clearance Tracker · K250119
Tempus ECG-Low EF
Last checked: Nov 19, 2026Latest source record: Jul 15, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Jul 15, 2025
Substantially Equivalent
Time to decision
180 days
Received Jan 16, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K250119
- Device name
- Tempus ECG-Low EF
- Applicant
- Tempus AI, Inc.
- Applicant location
- Chicago, IL
- Received
- Jan 16, 2025
- Decided
- Jul 15, 2025
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 870.2380
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QYE. The earliest in FDA's data is K232699, decided Sep 28, 2023.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K250119
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Tempus AI, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Tempus ECG-MR510(k)
K254297 · Decided Sep 25, 2026 · 268 days after receipt
Device type: Atrial Fibrillation Risk Prediction Machine Learning-Based Notification Software (SBQ) · Cardiology
- Tempus ECG-PH510(k)
K253699 · Decided Aug 21, 2026 · 270 days after receipt
Device type: Pulmonary Hypertension Machine Learning-Based Notification Software (SAT) · Cardiology
- xR IVD510(k)
K241868 · Decided Sep 19, 2025 · 449 days after receipt
Device type: Next Generation Sequencing Based Tumor Profiling Test (PZM) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.